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Abstract
Background: Lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of
severity from Wolman Disease to Cholesterol Ester Storage Disease. Recently enzyme replacement therapy with
sebelipase alpha has been approved by drug agencies for treatment of this lysosomal disease.
Ezetimibe is an azetidine derivative which blocks Niemann Pick C1-Like 1 Protein; as its consequence, plasmatic
concentration of low density lipoproteins and other apoB-containing lipoproteins, that are the substrate of lysosomal
acid lipase, are decreased. Furthermore, ezetimibe acts by blocking inflammasome activation which is the cause of liver
fibrosis in steatohepatitis and in lysosomal storage diseases.
Results: Two patients with Cholesterol Ester Storage Disease were treated with ezetimibe for 9 years and a third patients
for 10 years. Treatment was supplemented with low dose of atorvastatin in the first two patients during the last 6 years.
All patients showed a significant reduction of alanine aminotransferase, cholesterol and triglyceride. Furthermore,
no progression of liver fibrosis was demonstrated.
Conclusion: In this observational case series, ezetimibe is effective, safe, and sustainable treatment for lysosomal
acid lipase deficiency. Further studies are warranted to demonstrate that ezetimibe is an alternative therapy to
enzyme replacement therapy.
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Background
Lysosomal Acid Lipase Deficiency (LAL-D) is an autosomal
recessive disease caused by pathogenic variants of the LIPA
gene leading to absent or decreased activity of LAL enzyme,
which results in a progressive lysosomal accumulation of
cholesteryl esters (CE) in hepatocytes, adrenal glands, intes-
tines and macrophage-monocyte cells [1].
Diseases secondary to LAL-D are a continuum, classically
divided into the complete LAL deficiency, causing infantile-
onset LAL-D (formerly known as Wolman Disease, WD),
and the LAL deficiency with residual enzymatic activity
leading to a childhood/adult-onset form (formerly known
as Cholesteryl Ester Storage Disease, CESD).
WD has its onset in the first month of life and it is
characterized by a progressive course leading to death
before 1 year of age [1]. Hepatosplenomegaly, steator-
rhea, abdominal distension, severe malabsorption with
resultant malnutrition, and adrenal insufficiency with ad-
renal calcification are the cardinal features of WD [2].
CESD has a less severe clinical course; isolated hepato-
megaly or hepatosplenomegaly, increased plasma trans-
aminases, type IIa or IIb hypercholesterolemia, and
hypoalphalipoproteinemia are the more common initial
presentations. Hepatic fibrosis with unpredictable pro-
gression to micronodular cirrhosis, as well as premature
atherosclerosis, can occur [3]. Intermediate clinical pre-
sentations are also reported, as well as prenatal forms
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characterized by non-immune fetal hydrops [1] and
asymptomatic elderly forms. [4].
In LAL-D, the typical plasma lipid profile, character-
ized by increased levels of total cholesterol (TC), low
density lipoprotein cholesterol (LDL-C) and triglycerides
(TG), and decreased levels of high density lipoprotein
cholesterol (HDL-C), is due to complex secondary meta-
bolic alterations.
LAL cleaves CE and TG of apoB-containing lipoproteins
(chylomicron remnants, intermediate density lipoproteins
and low density lipoproteins), which are recognized by a
receptor localized on the cell membrane, internalized by
endocytosis, fused to endosome and carried to lysosome;
after enzymatic degradation, free cholesterol and fatty
acids are released by lysosome [5].
In LAL-D, the reduced efflux of free cholesterol from
lysosome causes up-regulation of hydroxymethylglu-
taryl-CoA reductase in the liver with increased choles-
terol synthesis and production of Very Low-Density
Lipoprotein (VLDL), as well as dysregulation of Low-
Density Lipoprotein Receptor (LDLR) expression, pos-
sibly leading to reduced cholesterol clearance [5, 6]. Fur-
thermore, decreased expression of the adenosine
triphosphate-binding cassette transporter A1(ABCA1),
and consequently reduced efflux of cholesterol to lipid-
free or lipid-poor apolipoprotein A-I (nascent HDL), is
the cause of reduced levels of HDL-C. [7].
The only therapeutic option had been liver transplant-
ation for many years, being statin therapy unable to pre-
vent liver fibrosis progression toward liver failure.
Recently, the enzyme replacement therapy (ERT) with
sebelipase alpha has been approved by Food and Drug
Administration and European Medical Agency as safe
and effective treatment for LAL-D [8]. However, import-
ant unanswered questions remain, such as if a long term
treatment with sebelipase alfa could modify hepatic con-
sequences of LAL-D, including liver fibrosis, cirrhosis or
need of liver transplant.
Ezetimibe, an azetidine derivative, blocks Niemann Pick
C1-like 1(NPC1L1) protein which plays a critical role in
intestinal cholesterol absorption and in enterohepatic cir-
culation of cholesterol. Consequently, it decreases plas-
matic concentration of Low Density Lipoprotein and
other apoB-containing lipoproteins, that are the substrate
of lysosomal acid lipase [9].
Here we report our experience on long-term treatment
with ezetimibe alone or in association with statin in
three patients with LAL-D, and we suggest the role of
this drug as substrate-reduction therapy.
Methods
This study is an observational case series and therefore
no controls are included. The patients consented publi-
cation for their clinical and genetic data.
Demographic, genetic and biochemical data of patients
at the time of diagnosis are reported in Table 1.
Patient 1 was born from unrelated parents; no family
history of dyslipidemia was reported. She was diagnosed
at the age of 9, when she was admitted to the hospital
presenting with hypercholesterolemia, severe hepatosple-
nomegaly, and hyperechoic liver on ultrasound, that
were detected during previous investigations for auto-
immune thrombocytopenia and were persistent after
normalization of platelets count. Light-microscopy and
immunohistochemistry of liver biopsy showed massive
vesicular steatosis, portal and septal fibrosis, portal infil-
tration of macrophages (CD68-positive), and lymphoid
cells with abnormal lipid deposits and lipid droplets in
hepatocytes and Kupffer cells (Fig. 1). Electron micros-
copy demonstrated lysosomal lipid storage in hepato-
cytes, macrophages, and Kupffer cells, as well as the
presence of birefringent cholesteryl ester crystals in he-
patocytes. She was initially treated with low-fat diet and
food supplements aiming to lowering cholesterol levels.
Subsequently, at the age of 18, she started ezetimibe at
daily-dose of 10 mg. After 3 years, ezetimibe was associ-
ated with low dose of atorvastatin (10 mg/day) to obtain
a further reduction of plasma lipids level. No adverse
events were recorded during lipid-lowering treatment.
No other drugs were used. The score of Alcohol Use
Disorders Identification Test (AUDIT) questionnaire at
the age of 22 was 3 at the age of 28 was 2 (a score of 7
or more in women indicates a strong likelihood of haz-
ardous or harmful alcohol consumption).
As her dizygotic twin sister was diagnosed with LAL-
D, patient 2 was examined as well. She was clinically
asymptomatic, but mild hepatosplenomegaly associated
with mixed hyperlipidemia was present and enzyme
assay and molecular analysis confirmed the diagnosis of
LAL-D. As her twin sister, she was initially treated with
Table 1 Demographic, clinical, biochemical and genetic data at the diagnosis
Sex Age at symptoms
onset (years)









1 F 7.5 Severe hepato-splenomegaly 9.2 c.894G > A //c.652 C > T 2,5a 134 7.26 1.36
2 F 9.9 Mild hepato-splenomegaly 9.9 c.894G > A //c.652 C > T 1,6a 137 7.83 2.28
3 M 18 Mild hepato-splenomegaly 20.5 c.894G > A//c.894G > A 0.03b 115 7.70 1.20
aLAL activity in blood lymphocytes (Reference values: 56.1 ± 7.6 nmol/mg protein/h);b LAL activity in Dried Blood Spot; (Reference values: 0.8–3.0 nmol/punch/h);
ALT reference 10–45 U/L, Cholesterol reference value below 5.17 mmol/L, Triglycerides reference value 0.3–1.7
Di Rocco et al. Orphanet Journal of Rare Diseases  (2018) 13:24 Page 2 of 6
low-fat diet and food supplements. At the age of 18, she
was started on ezetimibe; as her twin sister, after 3 years
she switched to combined therapy with the addition of
atorvastatin 10 mg/day. No other drugs were used.
AUDIT score at the age of 22 was 5, and at the age of 28
was 3. Patients 1 and 2 were both already treated with
ezetimibe at the time of enrollment the phase 3 sebeli-
pase alpha trial and they were not enrolled since their
alanine aminotransferase(ALT) levels already were less
than 1.5 times the upper limit of normal (eligibility crite-
rium for enrollment).
Patient 3 was born from unrelated parents. Family his-
tory of dyslipidemia was not reported. He was diagnosed
during evaluation for inguinal lymphadenopathy associ-
ated with increased hepatic transaminases and mild hepa-
tosplenomegaly, unresponsive to anti-inflammatory and
antibiotic treatment. At the time of diagnosis, hepatic
elastography by Fibroscan demonstrated mild fibrosis
(stiffness kPa 6.8; reference values: stiffness < 5 kPa corre-
sponding to Metavir score F0, stiffness < 8.9 kPa to Meta-
vir score F1). Liver biopsy showed enlargement of hilar
periportal spaces secondary to fibrosis, and obstruction by
foamy and pigmented histiocytes, with mild lymphoid in-
filtration, highly suggestive for LAL deficiency. Immedi-
ately after the diagnosis, he was treated with ezetimibe at
daily-dose of 10 mg/day for 10 years, without addition of
statin; no adverse events were recorded. No other drugs
were used. He denied alcohol consumption.
Results
After 9 years of treatment in Patients 1 and 2, and
10 years of treatment in Patient 3, all three subjects
showed reduction of ALT, TC and TG (Table 2, Fig. 2)
and mild liver fibrosis by hepatic elastography with
Fibroscan: Patient 1 stiffness 7.0 kPa; Patient 2 stiffness
7.9 kPa; Patient 3 stiffness 7.0 kPa.
Discussion
Here we report a long term study of 3 patients affected
by LAL-D treated with ezetimibe alone or associated
with statin.
The target of ezetimibe is NPC1L1 protein, which is
widely present in many human tissues, with highest
expression in small intestine and in liver. The inhibition
of NPC1L1 by ezetimibe reduces the mobilization of CE
and TG to the liver through the receptor-mediated
uptake of chylomicron remnant particles by decreasing
cholesterol absorption in the small intestine and entero-
hepatic circulation of cholesterol. It also reduces liver
Fig. 1 a Liver histopathology (H&E 10 X). H&E shows uniform microvesicular steatosis in hepatocytes. b: Immuno histochemical stain for CD68
shows portal infiltration of macrophages with lipid storage
Table 2 Biochemical data before and after ezetimibe treatment
Patient 1 Patient 2 Patient 3
Baseline E10 E10 + A10 Baseline E10 E10 + A10 Baseline E10
ALT (IU/L) 137.2 ± 37.1 79.1 ± 12.8** 88.5 ± 28.5** 186.7 ± 41.8 88.2 ± 26.5** 84.9 ± 21.1** 115.0 76.3 ± 7.2
TC (mmol/L) 7.36 ± 0.75 5.54 ± 0.50** 4.40 ± 0.82**† 7.98 ± 0.84 6.59 ± 1.22** 4.37 ± 0.42**† 7.70 5.92 ± 0.44
HDL-C (mmol/L) 0.96 ± 0.07 1.01 ± 0.06 0.95 ± 0.06 0.95 ± 0.07 0.96 ± 0.05 0.93 ± 0.07 0.82 0.80 ± 0.04
LDL-C (mmol/L) 5.60 ± 0.77 3.94 ± 0.55** 2.92 ± 0.78**† 6.17 ± 0.80 5.02 ± 1.19* 2.87 ± 0.40**† 6.34 4.71 ± 0.42
TG (mmol/L) 1.94 ± 0.62 1.25 ± 0.24* 1.18 ± 0.43* 2.24 ± 0.47 1.43 ± 0.63* 1.29 ± 0.45** 1.25 0.82 ± 0.19
Baseline values were calculated as mean values of the 3 years preceding the start of treatment for patient 1 and patient 2 and as value at the diagnosis, before
the start of treatment for patient 3; E10 = ezetimibe 10 mg/day; A10 = atorvastatin 10 mg/day. Wilcoxon test: *P < 0.05 vs baseline; **P < 0.02 vs baseline; †P < 0.02
vs E10. ALT reference 10–45 IU/L; Total Cholesterol (TC) reference value below 5.17 mmol/L, Triglycerides (TG) reference value 0.3–1.7 mmol/L, HDL cholesterol
(HDL-C) reference value above 1.16 mmmol/L, LDL cholesterol (LDL-C) reference value below 3.36 mmol/L
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cholesterol stores, and increases LDL clearance with
final effect of decreasing plasma LDL-C levels [9].
Being LDLs and the other apoB-containing lipopro-
teins the substrate of lysosomal acid lipase, the mechan-
ism of action of ezetimibe could be considered similar to
that of other drugs acting as substrate reduction therapy.
Substrate reduction therapy is based on the concept
that, in case of a defect of a catalytic enzyme, the reduc-
tion of substrate molecules flux reduces the storage of
these molecules. An example of this treatment is eliglu-
stat, licensed for Gaucher disease [10].
In LAL-D, as well as in other lysosomal diseases, en-
zyme deficiency is not only the cause of storage of
under-degraded molecules, but also the reason of gener-
alized lysosome dysfunction, impaired autophagy, and
inflammasome activation leading to hepatic fibrosis [11].
Abnormal activation of innate immunity is also reported
in non-alcoholic steatohepatitis (NASH) and non-
alcoholic fatty liver disease (NAFLD), which require
NOD-like receptor protein 3 (NLRP3) inflammasome
activation for fibrosis development [12].
In animal model of LAL-D and in a patient with LAL-
D, as well as in NAFLD and NASH patients, ezetimibe is
reported to be effective to reduce hepatic disease.
In lal−/− mice treated with ezetimibe (20 mg/day/kg/
bw) for 4 weeks, starting from 21 days of life, Chuang
demonstrated a significant decrease of both liver mass
and liver cholesterol concentration, as well as ALT levels
[13]. Data about plasma cholesterol in lal−/− mice were
not significant because, differently from humans, the
animal model does not develop dyslipidemia. More re-
cently, Chuang measured rates of cholesterol synthesis
in vivo in the liver and in small intestine of lal−/− mice
treated with ezetimibe; he demonstrated a reduction of
esterified cholesterol storage in the liver and in the small
intestine, even though the rates of liver and small intes-
tine cholesterol synthesis were comparable or exceeded
those in matching untreated lal−/− mice. These data
show the importance of cholesterol intestinal absorption
for the storage of cholesteryl esters in the liver of lal−/−
mice [14]. Furthermore, in animal models ezetimibe
ameliorates steatohepatitis by autophagy induction
through AMP protein kinase activation, transcrip-
tional EB nuclear factor translocation, and NLRP3
inflammasome inhibition [15]. Therefore, ezetimibe
has a double effect on the liver, by reducing CE stor-
age in hepatocyte, and by inhibiting inflammasomes,
which lead to liver fibrosis.
There are only two full reports of LAL-D patient
treated with ezetimibe. In a 18 year-old CESD subject,
treated with ezetimibe associated with lovastatin (40 mg/
day) for 12 months, the combined treatment not only re-
sulted in a significant reduction of plasma concentration
of TC and TG, but also in reduction of ALT and liver
size, suggesting a decrease in the CE accumulation [16].
Cameron reported a 35 year-old woman, followed over
two decades and previously treated with atorvastatin or
rosuvastatin, and subsequently with the combination of
atorvastatin and ezetimibe (40 and 10 mg/day, respect-
ively) for 2 years, with normalization of lipid profile and
liver function tests [17].
Besides, the efficacy of ezetimibe on hepatic disease
has been shown in NAFLD, NASH and related condi-
tions in humans [18–24].
Concerning the effect of ezetimibe in lipid lowering,
even if ezetimibe is indicated for primary hypercholester-
olemia, it is often used as an add-on therapy, being sta-
tins more potent lipid lowering medications and first
Fig. 2 Baseline values (calculated as mean values of the 3 years preceding the start of treatment) in comparison with mean values during ezetimibe
treatment and during ezetimibe and statins treatment of Alanine transaminase (ALT), Total Cholesterol (TC), LDL- Cholesterol (LDL-C), HDL Cholesterol
(HDL-C), Triglycerides (TG). In order to make data comparable, values are expressed as a ratio with maximum or minimal normal values for age according
to our laboratory. ALT reference 10-45 IU/L; Total Cholesterol (TC) reference value below 5.17 mmol/L, Triglycerides (TG) reference value 0.3–1.7 mmol/L,
HDL cholesterol (HDL-C) reference value above 1.16 mmmol/L, LDL cholesterol (LDL-C) reference value below 3.36 mmol/L. E10 = ezetimibe 10 mg/day;
A10 = atorvastatin 10 mg/day
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line treatment of dyslipidemias. Bernestein reviewed 132
CESD patients, 35 of them were treated with statins for
hyperlipidemia. Fifteen patients treated with statins had
biopsy findings with fibrosis, cirrhosis or other typical
pathologic abnormalities CESD-associated, but no long-
term or sequential follow-up data reported. The other
12 patients had multiple liver biopsies, but there were
no cases whose liver histology improved; 6 patients
required transplantation or died from liver failure. These
findings emphasize the lack of efficacy of statins in
ameliorating liver disease or preventing its progression
even if TC and LDL-C decrease [25].
The patients here reported have been treated with eze-
timibe for 9 and 10 years, with a significant reduction of
ALT level as well as a reduction of total cholesterol,
LDL-C and TG levels. None of the patients was followed
by liver biopsy and we cannot exclude spontaneous im-
provement in ALT as liver cirrhosis is found in histology,
but no progression of liver disease is demonstrated in
our three patients, who only have a mild fibrosis after
9 years (patient 1 and patient 2) and 10 years (patient 3)
of treatment on Fibroscan elastography.
Concerning the control of hyperlipidemia, ezetimibe
was associated with statin in the patient 1 and in the pa-
tient 2, but retrospectively we are unsure about the need
to add statin. The clinical outcome observed in patient
3,who was treated with ezetimibe alone, raises the ques-
tion if there was further benefit in adding a statin.
The ALT levels reduction was the primary end point
of clinical trial with sebelipase alpha, whereas the reduc-
tion of TC, LDL-C, and TG levels were secondary end
points of the same study [8]. Therefore, it is appropriate
to compare the efficacy of ezetimibe with ERT efficacy.
Clinical trials have demonstrated that sebelipase alpha
is efficacy in reducing these surrogate outcomes but it is
uncertain from the original clinical trial data whether
sebelipase alpha delays or stops disease progression to
cirrhosis, hepatocellular carcinoma, and need for liver
transplant. Another important issue is related to man-
aging access to ERT.
In infants under 6 months, LAL-D is rapidly progres-
sive and associated with a very short life expectancy. On
the other hand, disease progression is highly variable in
patients presenting with symptoms of LAL-D in child-
hood or adulthood. Therefore, there is wide consensus
in ERT for infants because it is the only treatment that
can prevent early death, but there is an open discussion
about treatment in patients whose symptoms are less se-
vere and whose condition is more slowly progressive.
Finally, the high cost of treatment with sebelipase
alpha poses a significant obstacle for some national
health system plans.
Based on the above, ezetimibe could be an alternative
oral therapy to ERT, while the association ERT-ezetimibe
or statins proposed by Block [26] seems not appropriate
mostly because of the cost.
Conclusion
In this observational case series ezetimibe is an effective,
safe, and sustainable treatment for LAL-D. Further stud-
ies are warranted to demonstrate that ezetimibe is an
alternative therapy to enzyme replacement therapy.
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